In light of its analysis, AETMIS recommends the following:
For the treatment of lung and bladder cancers and superficial esophageal cancers, PDT (PF) should be used only for clinical research purposes and should not be authorized for public coverage.
For the palliative treatment of advanced esophageal cancer, PDT (PF) should be considered a possible option when recognized treatments are contraindicated and should undergo further clinical research.
For the treatment of Barrett's esophagus, PDT (PF) should be fully assessed before it is introduced into current practice. A technology watch should be implemented to track technological advances in PDT in general and its new applications in particular.